$ News

Vivid Dx Appoints Diagnostics Veteran John Sperzel as Chief Executive Officer and Board Member

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

T2 Biosystems Inc (TTOO) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...

T2 Biosystems: Q3 Earnings Snapshot

T2 Biosystems Announces Third Quarter 2024 Financial Results

T2 Biosystems, Inc. (TTOO) Q3 2024 Earnings Call Transcript

T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

Q3 2024 T2 Biosystems Inc Earnings Call

T2 Biosystems, Inc. (TTOO) Business Update Conference Call Transcript

CAH Stock May Gain Following the Distribution Deal With T2 Biosystems

T2 Biosystems to Host Business Update Call on October 10, 2024

T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results

T2 Biosystems reports 35% rise in Q3 revenue

T2 Biosystems enters exclusive U.S. agreement with Cardinal Health